{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:39:58Z","timestamp":1792719598269,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":5185,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1111\/j.1538-7836.2008.03092.x","type":"journal-article","created":{"date-parts":[[2008,7,19]],"date-time":"2008-07-19T09:39:20Z","timestamp":1216460360000},"page":"1736-1741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits"],"prefix":"10.1016","volume":"6","author":[{"given":"P.C.","family":"WONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"WATSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"CRAIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate\u2010receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1053\/euhj.2000.3234","article-title":"Clopidogrel does not suppress blood markers of coagulation activation in aspirin\u2010treated patients with non\u2010ST\u2010elevation acute coronary syndromes","volume":"23","author":"Eikelboom","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta\u2010analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0030","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0035","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"Pinto","year":"2007","journal-title":"J Med Chem"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0040","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.910.910","article-title":"Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor","volume":"108","author":"He","year":"2006","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1111\/j.1538-7836.2008.03092.x_bb0050","article-title":"Apixaban, an oral direct, factor Xa inhibitor: single\u2010dose safety, pharmacokinetics and pharmacodynamics in healthy subjects","volume":"5","author":"Frost","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0055","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0060","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep\u2010vein thrombosis. The Botticelli DVT dose\u2010ranging study","volume":"6","author":"B\u00fcller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0b013e31803e8772","article-title":"Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits","volume":"49","author":"Wong","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0070","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low\u2010dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09537100701694144","article-title":"The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro\u2010inflammatory platelet responses","volume":"19","author":"Judge","year":"2008","journal-title":"Platelets"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3565(24)38889-5","article-title":"Nonpeptide factor Xa inhibitors: II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis","volume":"295","author":"Wong","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0085","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1124\/jpet.102.040089","article-title":"Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally\u2010active pyrazole antithrombotic agent, on arterial thrombosis in rabbits","volume":"303","author":"Wong","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.thromres.2005.11.015","article-title":"Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat","volume":"118","author":"Daykin","year":"2006","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0095","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1161\/01.ATV.19.10.2554","article-title":"Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats","volume":"19","author":"Feuerstein","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/01.fjc.0000179000.93154.e0","article-title":"The antithrombotic effect of melagatran in combination with clopidogrel and\/or aspirin (carotid artery primary thrombosis study)","volume":"46","author":"Hong","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11239-007-0017-9","article-title":"Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and\/or clopidogrel improves low\u2010dose antithrombotic activity without enhancing bleeding liability in rabbits","volume":"24","author":"Wong","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cct.2006.04.005","article-title":"The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee","volume":"27","author":"Boudes","year":"2006","journal-title":"Contemp Clin Trials"},{"key":"10.1111\/j.1538-7836.2008.03092.x_bb0120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1586\/14779072.5.6.1013","article-title":"Efficacy and safety of fondaparinux in patients with acute coronary syndromes","volume":"5","author":"Bassand","year":"2007","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2008.03092.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622139425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622139425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2008.03092.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:44:47Z","timestamp":1761533087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622139425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1538783622139425"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03092.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03092.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}